stockrow
Saturday 7 November 2026
Export OKUR’s income statement to Excel — free account
OnKure Therapeutics, Inc.
OKUR Healthcare Biotechnology
- EPS
- +67.2%
- Free cash flow
- +22.1%
Quarter to September 2026, against a year earlier
2.79
0.26
+10.28%
Follow OKUR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 1 | 1 | +63.3% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (12) | (19) | (40) | (52) | (35) | (53) | (60) | (62) | +29.8% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (12) | (19) | (40) | (52) | (35) | (53) | (60) | (62) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (63.83) | (95.98) | (21.90) | (21.20) | (124.41) | (15.28) | (4.40) | (2.77) | (36.0%) | ||||||
| Cash flow | — | — | — | (64.22) | (91.40) | (20.94) | (19.33) | (121.73) | (14.83) | (3.83) | (0.96) | (37.5%) | ||||||
| Capex | — | — | — | (0.04) | (0.12) | (0.11) | (0.14) | (0.87) | (0.02) | 0.00 | 0.00 | (32.5%) | ||||||
| Free cash flow | — | — | — | (64.26) | (91.52) | (21.04) | (19.48) | (122.59) | (14.84) | (3.84) | (0.96) | (37.5%) | ||||||
| Book value | — | — | — | 115.63 | 249.53 | 81.14 | 40.81 | 98.60 | 30.12 | 4.16 | 3.16 | (42.6%) | ||||||
| Shares, m | — | — | — | 0 | 0 | 2 | 2 | 0 | 3 | 14 | 32 | +102.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (13) | (19) | (38) | (47) | (35) | (51) | (52) | (48) | +26.7% | |||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +36.9% | ||||||
| Free cash flow | — | — | — | (13) | (19) | (38) | (48) | (35) | (51) | (52) | (48) | +26.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 22 | 50 | 148 | 99 | 26 | 102 | 55 | 157 | +16.1% | |||||
| Net debt | — | — | — | (25) | (54) | (148) | (101) | (30) | (111) | (59) | (163) | +15.5% | ||||||
| Shareholders’ equity | — | — | — | 23 | 51 | 147 | 100 | 28 | 104 | 56 | 158 | +16.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (97.52) | (48.22) | (38.01) | (39.63) | (49.07) | (69.93) | (67.24) | (51.56) | +30.3 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 38.12 | 59.67 | (75.68) | (42.04) | 3,772.54 | (5,304.43) | (74.39) | (55.18) | (112.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 23 | 32 | 48 | 8 | 35 | 45 | — | +14.4% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 6 Nov 2026
OnKure Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | $106.9M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| VYGR Voyager Therapeutics, Inc. | $106.0M | — (loss-making) | — (loss-making) | −69.97% (below 0%: shrinking) | n/m | +37.08% (above 0%: growing) | 100.00% | (658.25%) | Compare |
| ANIX ANIXA BIOSCIENCES INC | $105.3M | — (loss-making) | — (loss-making) | 0.00% | n/m | −17.14% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NBP NovaBridge Biosciences | $105.3M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $102.9M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| HURA TuHURA Biosciences, Inc. | $102.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OKUR OnKure Therapeutics, Inc. | $102.3M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | |
| IMUX Immunic, Inc. | $99.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $98.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| Median of peers | $104.1M | — | — | −79.25% | — | −21.96% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 21 April 2026
Ownership
Directors and executive officers, together
2.17%
AI Biotechnology LLC
19.99%
RA Capital Healthcare Fund, L.P.
9.90%
Acorn Bioventures, L.P.
9.71%
Stepstone Master G, L.P.
6.59%
ADAR1 Capital Management
6.03%
Trails Edge Capital Partners, LP
5.97%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement